Journal
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
Volume 142, Issue 3, Pages 408-419Publisher
COLL AMER PATHOLOGISTS
DOI: 10.5858/arpa.2017-0106-SA
Keywords
-
Funding
- Grants-in-Aid for Scientific Research [16H05167] Funding Source: KAKEN
Ask authors/readers for more resources
The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available